GAITHERSBURG, Md., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT) (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, ...
Zacks Small Cap Research on MSN
MTVA: Positive results for 48 mg cohort in phase 1b trial of DA-1726
By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update Positive Results for 8-week 48 mg Cohort ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results